Effect of Teneligliptin in comparison with Voglibose as an add on therapy in reducing microvascular complications in type II Diabetes Mellitus patients – A Prospective randomized control trial Sivasankari V.1,*, Manivannan E.2 1Professor, Department of Pharmacology, Vinayaka Mission’s Kirupananda Variyar Medical College and Hospitals, Salem - 636 308, Vinayaka Mission’s Research Foundation (Deemed to be University), Tamilnadu, India 2Professor and HOD, Department of Pharmacology, Vinayaka Mission’s Kirupananda Variyar Medical College and Hospitals, Salem - 636 308, Vinayaka Mission’s Research Foundation (Deemed to be University), Tamilnadu, India *Corresponding Author E-mail: drvsivasankari@gmail.com
Online Published on 07 February, 2024. Abstract Background The strict glycaemic control postpones all the microvascular and macrovascular complications. In type 2 diabetes the initiation of metformin is the cornerstone in reducing blood sugar. The next option is either insulin or oral hypoglycaemic agents. The DPP-4 inhibitors like gliptins have the advantages of less incidence of hypoglycaemia, good safety profile and can be combined to any oral hypoglycaemics. The meta-analysis showed that teneligliptin has less adverse profile in number of Japanese and Korean studies. It was proved that the fasting glucose and postprandial glucose substantially reduced with a potential benefit of reducing cholesterol, thereby reducing the risk of cardiovascular diseases. The advantage of using this drug as is does not worsen the hepatic and renal status. Voglibose an α-glycosidase inhibitors delay the glucose absorption from GIT hence effective in reducing postprandial hyperglycaemia. Methods This prospective randomized controlled study was designed to compare the efficacy of teneligliptin and voglibose as an add on therapy on patients with uncontrolled blood sugar in addition to metformin 500mg BD and glimepiride 2 mg OD. Totally 80 patients were included between the age groups of 40 to 70 years. Patients were divided into two groups 40 patients each, group A were given teneligliptin and group B patients were given voglibose for a period of 6 months. At the end of 3rd month and 6th month investigations were done for FBS, PPBS and HbA1c. Statistical methods: Data were tabulated and results were analysed by using Analysis of Variance. AP value of <0.05 was considered as statistically significant. Results At the end ofsix months group II showed significant reduction in fasting blood sugar and post-prandial blood sugar level. A significant reduction in FBS, PPBS, HbA1c is seen in both the groups, where teneligliptin has a favourable glucose reduction along with voglibose. Conclusions Our study concludes that teneligliptin is better than voglibose as the 2nd line add on therapy to sulphonylureas, metformin or insulin. Top Keywords Teneligliptin, Voglibose, Type II diabetes mellitus, DPP-4 inhibitor, HbA1c. Top |